Target intelligence / Profile preview

Advanced glycation end-product protein-protein cross-links (AGE cross-links) (AGE cross-links)

Target
AGE cross-links
Molecular classification
Other, Non-enzymatic protein modification
01

Overview

Advanced glycation end-products (AGEs) are a heterogeneous group of molecules formed through the non-enzymatic reaction between reducing sugars and the amino groups of proteins, lipids, or nucleic acids [PMID: 24354186]. Protein-protein cross-links represent a specific subset of AGEs that covalently bond adjacent protein fibers, leading to increased tissue stiffness and loss of elasticity in the extracellular matrix [PMID: 11733224]. These cross-links are particularly prevalent in long-lived proteins like collagen and elastin, contributing significantly to the pathology of aging, diabetic complications, and cardiovascular stiffening [PMID: 15356013]. In disease states, the accumulation of AGE cross-links impairs organ function and triggers inflammatory signaling through the Receptor for Advanced Glycation End-products (RAGE) [PMID: 12488523]. Therapeutic strategies involve "AGE-breakers" designed to cleave these covalent bonds or inhibitors that prevent their formation by scavenging reactive intermediates [PMID: 11113300]. Despite promising preclinical data showing reversal of arterial stiffness, clinical translation has faced challenges regarding efficacy and safety in human trials [PMID: 18445619].

Other names
AGEsAdvanced glycation end-productsMaillard reaction productsProtein-protein cross-linking
02

Mechanism of action

Cleavage of alpha-diketone bonds in protein-protein cross-links (AGE-breaking) [PMID: 9535621]; Inhibition of AGE formation by scavenging reactive dicarbonyl precursors [PMID: 15155812].

03

Biological functions

Signal transductionCell deathOther
04

Disease associations

Cardiovascular diseaseInflammationNeurodegenerative diseaseOther
05

Safety considerations

Potential for off-target cleavage of physiological cross-linksLimited clinical efficacy in human trialsSystemic toxicity of early-generation inhibitors
06

Interacting drugs

Alagebrium

4 more in the full profile.

07

Biomarkers

PentosidineN-epsilon-(carboxymethyl)lysine (CML)Skin autofluorescenceMethylglyoxal

Beyond the preview

Go deeper on Advanced glycation end-product protein-protein cross-links (AGE cross-links) (AGE cross-links).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced glycation end-product protein-protein cross-links (AGE cross-links) (AGE cross-links).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call